Scientists and researchers from around the globe met last week for the 17th Conference on Retroviruses and Opportunistic Infections (CROI), a four-day conference presenting the latest research about prevention, treatment, and insight into HIV/AIDS and its complications.

Topics ran the gamut from novel therapies to public health strategies aimed at the global pandemic.

What follows are a few of the developments from the conference.

The View From NIAID

On the first day of the conference, Dr. Anthony Fauci, director of the National Institute of Allergy and Infectious Diseases (NIAID), addressed…

Gilead Sciences, Inc. announced, after 24 weeks of a Phase 2 clinical trial, that its “Quad” regimen for the treatment of HIV is comparable in efficacy with another popular combination therapy known as Atripla (efavirenz/emtricitabine/tenofovir).

Quad therapy, which is an integrase inhibitor-based treatment, targets the action of an enzyme necessary for HIV to replicate itself. Like Atripla, Quad therapy simplifies dosing by combining different drugs into a single pill, making adherence to a therapeutic regimen easier for HIV patients.

The ongoing study compared the investigational once-daily, fixed-dose regimen of four…